3.3800 +0.08 (2.42%)
After hours: 7:55PM EST
|Bid||3.2700 x 3100|
|Ask||3.3000 x 4000|
|Day's Range||3.0300 - 3.3000|
|52 Week Range||1.8700 - 5.7500|
|Beta (5Y Monthly)||0.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Those following along with Amyris, Inc. (NASDAQ:AMRS) will no doubt be intrigued by the recent purchase of shares by...
If you own shares in Amyris, Inc. (NASDAQ:AMRS) then it's worth thinking about how it contributes to the volatility of...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Amyris, Inc. (Nasdaq:AMRS) is pleased to announce that it has entered into a consulting agreement with John Ziegelman, formerly a senior portfolio manager at Wolverine Asset Management, one of the company's top 15 shareholders. Ziegelman has over 30 years' experience investing in and advising small-cap public companies. In addition to his time with Wolverine, Ziegelman has held senior positions at Shearson-Lehman Brothers, Kidder Peabody, Citadel, and Carpe Diem Capital. Ziegelman holds an MBA from the University of Chicago and a BA from the University of Michigan. The scope of the two-year consultancy, which began on November 20, focuses on advising Amyris on supporting its capital markets activities, further simplifying the balance sheet and helping the company further diversify and increase its institutional shareholder base.
Beyond Meat is just the beginning of a new emerging cohort of innovative companies. These innovators are changing how we feed the planet without consuming more of its resources.
Lavvan announced the appointment of Neil Closner as its new chief executive officer on Thursday. Closner left his position as CEO of MedReleaf and will be joining Lavvan's team along with seven other members of MedReleaf’s leadership team, Lavvan said in a press release. The company is collaborating with Amyris (NASDAQ: AMRS) on the development of fermentation-based technology that will add knowledge to the way cannabinoids can be applied within the industry.
Temasek Holdings is a Singapore-based global investment company with a long-term-focused investment horizon. It was founded back 1974, and since then it has achieved compounded annualized return of 15% in Singapore dollar terms. Even though it is based in Singapore, it offers 11 offices around the world. Temasek Holdings look for the investment opportunities in […]
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viacom Finally Renews Contract with AT&T(Continued from Prior Part)AT&T’s stock price movementAT&T (T) stock rose 0.03% on March 22. The stock has fallen 0.2% in March, while it has risen 10.7% in the year-to-date period. The market
Amyris, which produces ingredients in the health and wellness, clean beauty and flavors and fragrances markets, said it has clinched a deal with newly formed LAVVAN Inc., which is working on bringing the first fermentation-derived cannabinoid products to market. The announcement comes after a previously announced term sheet and includes further milestone payments related to additional targeted products. Amyris, with its expertise in terpenes, said it will leverage its automated processes and R&D staff in the development of cannabinoid pathways.